Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × NKTR-255 × Clear all
NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Stanford University

Phase 1 Active not recruiting
56 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡